drugset / Trial / NCT00848965
A Randomised, Double Blind, Placebo Controlled, 4 Period, Incomplete Block, Crossover Study Assessing the Dose-response Curve of Fluticasone Propionate in an Antigen Challenge Chamber
RandomizedCrossoverTriple-blindTreatment
Summary
This is a single-centre, randomised, double-blind, four-period, incomplete block, crossover study, with 8 days repeat dosing of intranasal Fluticasone Propionate (25, 50, 100, 200ug) and/or placebo in the Vienna Challenge Chamber in subjects with allergic rhinitis.
Timeline
- Start
- 2007-10
- Primary completion
- 2008-01
- Completion
- 2008-01
Outcome
Met primary endpoint
registry analysis (superiority or other test); Placebo vs 25 µg FP; Mean Difference (Final Values) -1.38 (95% CI -2.08 to -0.68) NCT00848965 ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Fluticasone propionate | Other / unclassified | 25 ug | Intranasal |
| Subject | Fluticasone propionate | Other / unclassified | 50 ug | Intranasal |
| Subject | Fluticasone propionate | Other / unclassified | 100 ug | Intranasal |
| Subject | Fluticasone propionate | Other / unclassified | 200 ug | Intranasal |